IL6 and hepatocellular carcinoma: In a study conducted by Lai et al., they found that the IL-6/STAT3 signaling pathway regulates the DNMT3b enzyme, and it can facilitate the development of resistance to the chemotherapeutic agent sorafenib by promoting the expression of OCT4, which, at the same time, led to a poor prognosis and outcome in HCC (57).